护城河对比

The 10-K names Broadcom, Marvell and Astera Labs as principal competitors that compete on 'some, but not all' of Credo's solutions, and discloses that the top 10 customers were approximately 90% of fiscal 2026 revenue with two customers at 10% or more each. A defensible technical position sold into a handful of buyers with that much leverage is narrow, not wide.

来源：sec.gov

宽阔：CUDA 软件平台及其开发者既有用户基础在整个 AI 训练技术栈上形成高昂的转换成本，由累计 $76.7B 研发投入护持，并被 FY2026 约 71% 的毛利率以及同比增长 68% 的数据中心营收（约占总额 90%）所强化——按 FY2026 10-K，这些是持久且难以复制的优势。

来源：sec.gov

The FY2025 10-K supports a real but bounded advantage. The Competition section says the company believes "mRNA as a medicine coupled with our capabilities across mRNA technology, drug discovery, development and manufacturing provide us with a competitive advantage," and the Intellectual Property section backs that with more than 260 issued or allowed U.S. patents or applications, more than 140 granted or allowed outside the U.S., 485 pending applications, and latest-to-expire granted patents on all three approved products projected to 2041 in the U.S. and 2036 in Europe. Item 1A cuts the band down from wide: it opens the competition risk with "The vaccine market, and pharmaceutical market more generally, is intensely competitive," says Moderna "ha[s] been excluded from selling our COVID vaccines in many European markets due to a competitor's contract with the European Commission, which does not lapse until year-end 2026," that in RSV it "entered a market already occupied by two larger competitors," and that rivals "have exploited and may in the future exploit their greater size, infrastructure, resources and experience." The same section reports net losses of $2.8 billion in 2025 and $3.6 billion in 2024 against 2025 total revenue of $1.9 billion.

来源：sec.gov

The filing states the products 'are based on our own optimized Serializer/Deserializer (SerDes) and Digital Signal Processor (DSP) technologies' and lists 'extent of IP protection and enforcement of rights' among the principal competitive factors in its market.

来源：sec.gov

持久优势建立在专有 IP 与软件之上：可在所有 NVIDIA GPU 上运行的全栈 CUDA 开发平台，加上数百个专有领域库/SDK/API，以及累计 $76.7B 研发投入所带来的 "inventions that are essential to modern computing"（NVIDIA 于 1999 年发明了 GPU）。按 FY2026 10-K 的业务章节，这一优势还被开发者生态系统的网络效应与 CUDA 转换成本进一步强化。

来源：sec.gov

The filing locates the advantage in a patent and know-how estate, not in customer lock-in or cost. Intellectual Property describes "an expansive, multi-layered IP estate" whose platform claims cover mRNA chemistry, sequence optimization, engineering elements, LNP delivery systems and "innovative processes for the manufacture and analysis of mRNA drug substance and formulated drug product," alongside "substantial proprietary know-how associated with related manufacturing processes" and a trademark portfolio of at least 1,400 registrations. Nothing in the filing claims switching costs or a cost advantage; Item 1A says the opposite, that competitors leverage "larger supply chains and greater purchasing power."

来源：sec.gov

The 10-K states 'We believe we are the only company in our industry offering a complete suite of high-performance connectivity solutions', while naming Broadcom, Marvell and Astera as principal competitors on parts of the portfolio — a co-leader's claim, attributed to the company, not an independently observed share.

来源：sec.gov

FY2026 Data Center revenue was $193.7B (~90% of the $215.9B total), up 68% YoY on the Blackwell ramp, and NVIDIA describes itself as "a data center scale AI infrastructure company reshaping all industries." The 10-K frames named rivals as parties who "provide or intend to provide" GPUs/accelerators — incumbent-leader positioning.

来源：sec.gov

The Business section opens with the company's own claim that "Moderna is a pioneer and leader in the field of mRNA medicine." The Competition section frames the commercial reality more narrowly as a contest against a small named set: "We largely compete against Pfizer and BioNTech for sales of our COVID vaccines, whose vaccine is also based on mRNA technology. We also compete against other vaccines, including Sanofi and Novavax's." It does not claim a rank anywhere, and it places Moderna behind in the other approved category: in RSV "we compete against Pfizer and GlaxoSmithKline, who entered the U.S. market prior to us, and our RSV sales have been minimal to date."

来源：sec.gov

The n-1 node advantage the filing describes lets Credo price against competitors from a lower cost base, but the same filing discloses two customers at 10% or more of revenue and a top-10 concentration near 90%, which is buyer leverage working the other way.

来源：sec.gov

FY2026 gross margin was 71.1% (75.0% in FY2025); per the 10-K MD&A the ~3.9pt decline reflects the Hopper HGX→Blackwell full-system mix shift and a one-time $4.5B H20 excess-inventory/purchase-obligation charge, not competitive price erosion. A low-70s% hardware gross margin evidences strong pricing power.

来源：sec.gov

Item 1A states that "certain U.S. private vaccine market practices, including regarding discounts, rebates and returns, may cause us to realize significantly lower revenues than list prices," and that "in some instances, our competitors have been able to offer more attractive terms than we can, and they may continue to do so in the future." On the flu candidate it says that in a well-developed market Moderna "may need to offer more favorable terms to gain market share (which we may be unable to do), which may negatively impact our profitability." The Commercial section adds that its markets are "characterized, particularly in the U.S. (our largest market), by a fragmented end customer base, unpredictability in orders and seasonality of deliveries."

来源：sec.gov

Upstream interconnect supplier: SerDes/DSP silicon and active cables sitting between accelerators, switches and optics inside AI data centers.

Upstream compute-platform supplier: NVIDIA sells full-stack data-center systems (GPU + Arm CPU + DPU + NVLink/InfiniBand networking + CUDA software) to cloud providers and enterprises, and relies on third-party foundry/assembly-test-packaging partners (e.g., SPIL, Amkor, Wistron, Fabrinet). Per the FY2026 10-K, several of its largest customers (hyperscalers such as Amazon, Alphabet, Microsoft) are simultaneously customers and emerging competitors developing internal accelerated-computing silicon.

A vertically integrated mRNA developer-manufacturer that sits between upstream licensors and government or retail buyers: it in-licenses the Penn modified-mRNA patents non-exclusively through Cellscript and mRNA RiboTherapeutics at low-single-digit royalties and NIAID's prefusion coronavirus spike and prefusion RSV F patents, manufactures drug substance at the owned Norwood MTC campus and individualized therapy at Marlborough, runs Moderna-built plants in the UK, Canada and Australia against multi-year government purchase commitments, and relies on CMOs for critical raw material production and fill-finish.

• Optical PAM4 DSPs 前三 · 中等 来源：sec.gov
• PCIe Retimers 挑战者 · 中等 来源：sec.gov
• SerDes Chiplets and SerDes IP licensing 细分市场 · 深 来源：sec.gov
• ZeroFlap Active Electrical Cables (AECs) 领先 · 深 来源：sec.gov
• ZeroFlap Optical Transceivers 挑战者 · 中等 来源：sec.gov

• CUDA accelerated-computing software platform (CUDA-X, NVIDIA AI Enterprise) 领先 · 深 来源：sec.gov
• Data Center AI accelerators (GPU — Blackwell/Hopper) 领先 · 深 来源：sec.gov
• Data-center networking / interconnect (NVLink, InfiniBand, Spectrum Ethernet, DPUs) 前三 · 中等 来源：sec.gov

• Intismeran autogene (mRNA-4157) 未知 · 中等 来源：sec.gov
• Spikevax 前三 · 中等 来源：sec.gov
• mNEXSPIKE 前三 · 中等 来源：sec.gov
• mRESVIA 挑战者 · 中等 来源：sec.gov
• mRNA-1010 seasonal influenza vaccine 未知 · 中等 来源：sec.gov

编辑先验，未经回测。

查看它究竟如何投票 →

编辑先验，未经回测。

查看它究竟如何投票 →

编辑先验，未经回测。

查看它究竟如何投票 →